771.0000 -30.10 (-3.76%)
NSE Jan 19, 2026 09:07 AM
Volume: 123
 

771.00
-3.76%
Deven Choksey
We maintain a positive FY26E outlook, expecting sustained double-digit growth across US, Ex-US, and RoW businesses. Growth across regions will be majorly driven by a healthy US pipeline, strategic expansion in RoW, and improved execution across India.
Alembic Pharma has lost -21.05% in the last 6 Months
More from Alembic Pharmaceuticals Ltd.
Recommended